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Abstract - Vitamin A is essential for the early development and normal functioning of the brain throughout life. A defi-
ciency of vitamin A is one of the leading causes of morbidity and mortality in developing countries, and subclinical defi-
ciency is probably present worldwide. The main active molecule in vitamin A is retinoic acid, which is involved in vision, 
the immune system, skin health, olfaction and cognition (learning, memory, spatial functions, olfaction, etc.) through 
processes of neuroplasticity and neurogenesis. Vitamin A is involved in the regulation of about one-sixth of the human 
genome. It has non-genomic actions in protein translation and paracrine actions. Retinal vitamin A aldehyde is crucial for 
day and night vision. The best-known manifestation of hypovitaminosis A is night blindness but in more severe cases, it 
causes blindness. In the hypothalamus, vitamin A, with information from the retina, acts in circadian and seasonal regula-
tion. Increased retinoic acid levels in the blood are associated with increased risk of depression, and lower levels have been 
connected with Alzheimer’s disease, Parkinson’s disease, cerebral ischemia, autistic spectrum disorders and schizophrenia. 
Higher doses and longer periods of treatment pose the threat of hypervitaminosis A. Vitamin A and its analogs are a prom-
ising new class of therapeutic agents in a wide spectrum of disorders, albeit with a narrow therapeutic window.  
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INTRODUCTION
Optimal levels of vitamin A are important from the 
embryonic stage to the end of life. A lack of micro-
nutrients is of the utmost importance and the World 
Health Organization (WHO, 2002) found deficien-
cies of iron, zinc and vitamin A in the top ten lead-
ing causes of death in developing countries. Vitamin 
A is a generic term for several related unsaturated 
molecules, retinoids, primarily involved in early de-
velopment and growth, proper functioning of the 
immune system, vision, reproduction, skin health 
and in central nervous system for neuroplasticity, 
neurogenesis and other important processes. (Ben-
ton, 2010; Tanumihardjo, 2011). The most impor-
tant forms of retinoids are retinol, which is an alco-
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hol, retinal, which is an aldehyde, and retinoic acid 
(RA), the active form. Carotenoids, the best known 
being beta-carotene, are called provitamin A and 
can be converted to retinol by the body (Food and 
Nutrition Board, 2001). 
We will focus on the importance of vitamin A in 
brain function and vision. Both nervous system and 
eyes are of ectodermal origin and share many simi-
larities. Vitamin A has important signaling functions 
in the human brain and needs subtle balance for op-
timal functioning. 
Metabolism
In intestinal resorptive cells, retinol is esterified to 
long-chain fatty acids and forms retinyl esters pack-
aged in chylomicrons (Berry and Noy, 2012). Under 
normal conditions, 90% of the body’s vitamin A is 
stored in the liver as retinyl ester. The liver releases 
retinol, which becomes attached in the blood to a 
complex of retinol-binding protein (RBP) and tran-
sthyretin (TTR). Vitamin A is transported into the 
cells by a membrane protein stimulated by retinoic 
acid 6 (STRA6) or by passive diffusion (Napoli, 2011). 
Retinol is oxidized in cells to retinal, and then to RA 
by retinaldehyde dehydrogenases (RALDH1/2/3) 
(Napoli, 2011; Shearer et al., 2012). Vitamin A acts 
in the organism mainly via its metabolite all-trans-
retinoic acid (atRA) within a narrow concentration 
range (Napoli, 2011). Vitamin A and RA act as a pro-
hormone-hormone pair. Vitamin A itself is not ac-
tive. There are genomic and non-genomic actions of 
RA. Retinoic acid activates gene transcription via RA 
receptors (RARs) α, β, and γ and retinoid X receptors 
(RXRα, β, and γ). Retinoic acid controls a sixth of 
the human genome (Luo et al., 2009). Non-genomic 
actions are regulation of kinases and protein trans-
lation, as well as diffusing out of the cell to activate 
neighboring cells in a paracrine way (Shearer et al., 
2012). 
Vitamin A and vision
Vitamin A is necessary for vision as it converts light 
into neural signals in the retina. Retinol is delivered 
to the eye via blood circulation and it builds up in 
pigmented epithelial cells. It is converted to retinal 
form, which combines with opsin and forms rho-
dopsin in rods and iodopsin in cones, molecules 
with the function of absorbing light involved in 
low-light vision (rods) and color vision (cones) 
(Wolf, 2001). Under the impact of light, the 11-cis-
retinal is isomerized to the all-trans form. The all-
trans retinal then separates from the opsin in a 
process named photobleaching. A nervous signal is 
transmitted down the optic nerve under the induc-
tion by isomerization. The all-trans form is after-
wards recycled again to the 11-cis-retinal form, and 
in a smaller quantity to all-trans-retinol as a depot 
in the epithelial cells of the retina. The other func-
tions of vitamin A in vision are the differentiation 
and functioning of the conjunctival membrane and 
cornea (Ross, 2010). It also connects perception of 
light with circadian and seasonal regulation in the 
hypothalamus depending on the duration of day-
light. Vitamin A deficiency leads to night blindness 
and potentially complete blindness. 
Vitamin A in development
Retinoic acid has the properties of a hormone and 
acts as a growth factor for epithelial and other cells, 
especially in the eye and brain during development 
(Tanumihardjo, 2011). In the adult brain, the retino-
ic acid signaling mechanism becomes more regional 
with different functions. Vitamin A deficiency im-
pedes growth, induces infertility and retinal degener-
ation. Stem cells require retinoids for normal differ-
entiation into erythrocytes and for iron mobilization 
into developing erythrocytes for incorporation into 
hemoglobin. Around one-third of children aged 0-5 
years are vitamin-A deficient; of these around 670 
000 pass away worldwide and up to 500 000 lose their 
sight (World Health Organization, 2009; Black et al., 
2008). Increased maternal consumption of vitamin 
A and some other retinoids during pregnancy is as-
sociated with birth defects, such as malformation 
of the eye, skull, lungs and heart (Solomons, 2006). 
Optimal vitamin A supplementation should be done 
cautiously as hypovitaminosis and hypervitaminosis 
are divided by a narrow margin.  
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Vitamin A deficiency
The most useful method of vitamin A body status as-
sessment is measurement of the plasma retinol level, 
but it does not show the liver vitamin depot. Vitamin 
A deficiency is defined as plasma retinol concentra-
tion lower than 0.70 mcmol/L, with concentrations 
of 0.70-1.05 mcmol/L being marginal (Food and Nu-
trition Board,). 
Primary vitamin A deficiency is the conse-
quence of inadequate food intake of provitamins/
carotenoids from vegetables and retinoids from an-
imal sources, as well as early weaning from breast 
milk. Secondary vitamin A deficiency is the result of 
chronic malabsorption of lipids, chronic diarrhea, 
insufficient bile production and release, smoking, 
inappropriate alcohol consumption and ageing. 
Usually the first sign of vitamin A deficiency is poor 
sight, especially at night, called night blindness, and 
further on xerophthalmia. Eventually keratomala-
cia occurs with the destruction of the cornea and 
complete blindness (Roncone, 2006). Vitamin A de-
ficiency decreases immunology defense both of hu-
moral and cell-mediated immunity, with increased 
morbidity and mortality from infectious diseases 
(Food and Nutrition Board, 2001). Another area of 
interest is the connection between vitamin A status 
and macular degeneration, a major cause of vision 
failure in elderly people, but research results are not 
conclusive. 
Vitamin A and brain function
Vitamin A plays an important role in maintain-
ing higher function in the central nervous system 
(Ono, yamada, 2012). It has been shown that RA is 
important in cognitive activities (Luo et al., 2009). 
Hippocampal long-term potentiation (LTP) and 
long-term depression (LTD), essential for memory 
formation in the hippocampus, are dependent on 
vitamin A (McCaffery et al., 2006). Vitamin A is 
also necessary for plasticity, neurogenesis and cir-
cadian rhythm mechanisms in the hippocampus 
(Shearer et al., 2012). Another important process is 
synaptic scaling, a plasticity phenomenon in which 
neurons adjust the strength of their synaptic net-
works according to external stimuli, which is de-
pendent on RA (Pozo, Goda, 2010). Human sup-
plementation with RA results in better learning, 
memory, and possibly executive functions (Ergun 
et al., 2012).
Another area of vitamin A function is the olfac-
tory system, which critically depends on neuronal 
plasticity (Rawson, LaMantia, 2006). Vitamin A is 
essential for both development and function of the 
olfactory system.
Recent studies have revealed the essential role 
of RA in the hypothalamus, more so in the arcuate 
nucleus, which regulates feeding and energy bal-
ance, and the ependymal layer that mediates trans-
duction of extrahypothalamic signals (Shearer et 
al., 2012). Energy balance and reproduction change 
with the seasons (photoperiodic changes depend-
ent on the length of the daytime). In the hypotha-
lamus, RA may be one of the triggers for seasonal 
weight control. The circadian cycle is also RA-de-
pendent and it can be connected to the role of RA 
in vision via the perception of daylight length. It 
is very probable that neurogenesis occurs in adult 
hypothalamus (crucial for energy balance regula-
tion), as stem cells producing functional neurons 
are found in this structure, and that RA signaling 
controls this process (Shearer et al., 2012). Neuro-
genesis occurred in the ependymal layer and the 
arcuate nucleus. 
Affective disorders
Retinoic acid is connected with affective disorders 
through retinoic acid receptor (RAR – member of 
the steroid/thyroid receptor family) control of cor-
ticotropin-releasing hormone (CRH) gene expres-
sion and activity of hypothalamic-pituitary-adrenal 
(HPA) axis (Chen et al., 2009). RARα increases CRH 
gene expression. In the paraventricular nucleus of 
patients with affective disorders, the density of RAR-
α-immunoreactive neurons and CRH-RAR-α dou-
ble-staining neurons is significantly increased (Chen 
et al., 2009). 
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Dementia
Lower plasma and cerebrospinal fluid concentrations 
of vitamin A and beta-carotene have been found in 
Alzheimer’s disease (AD) patients (Ono, yamada, 
2012). Even more importantly, there is some evidence 
that these vitamins slow the progression of AD. It is 
hypothesized that the degradation of RA signaling 
might influence the initiation and development of 
AD. Supplementation with RA improves learning 
and spatial functions (Ormerod et al., 2011). APP/
PS1 transgenic mice treated with tretinoin, the acid 
form of vitamin A, also known as all-trans retinoic 
acid or atRA, display a substantial decrease in brain 
amyloid-beta deposition, tau phosphorylation and 
decreased activation of microglia and astrocytes 
(Ding et al., 2008). According to the aforementioned 
data, RA can be a promising prophylactic and thera-
peutical agent in AD.
Parkinson’s disease
Retinoic acid is active in the dopaminergic system of 
substantia nigra. A protective effect of RA on nigros-
triatal neurons in an animal model of Parkinson’s 
disease was recently shown (yin et al., 2012). Differ-
ent protective actions of RA dopaminergic neurotox-
ins have been demonstrated in vitro. 
Cerebral ischemia
In many experiments, the neuroprotective effect of 
RA against cerebral ischemia in rats was document-
ed (yin et al., 2012). In the experimental model of 
ischemia, RA inhibited H2O2-induced apoptosis in 
mesangial cells and improved survival during an-
oxia/glucose deprivation. 
Autistic spectrum disorders
Fragile X syndrome results from mutations in the 
FMR1 gene. The RA and fragile X mental retarda-
tion protein (FMRP) are both involved in the regu-
lation of brain plasticity (Soden, Chen, 2010). The 
known importance of RA in fetal development can 
be a possible explanation for at least some of the neu-
rodevelopmental disturbances in autism. Oxytocin is 
released in the brain via the CD38 transmembrane 
protein and is essential for social behavior, and it is 
linked to autism spectrum disorders (Shearer et al., 
2012). Individuals with autism spectrum disorders 
have lower plasma levels of oxytocin than unaffected 
persons. There are genetic links between CD38 and 
autism (Riebold et al., 2011). In vitro studies found 
that RA could induce CD38 expression and conse-
quently increase oxytocin release, which is of poten-
tial therapeutical importance (Shearer et al., 2012).
Schizophrenia
Retinoic acid regulates GABAergic interneurons 
of the cortex, olfactory bulb and amygdala, and 
dopaminergic neurons of the substantia nigra 
(Shearer et al., 2012). As RA regulates many genes, 
some of them are also candidate genes involved in 
schizophrenia. Recently the retinoic acid induced 1 
(RAI1) gene has been associated with severity and 
response to treatment in schizophrenia (Toulouse et 
al., 2003).
Recommended daily intake and therapeutical dose
The Recommended Dietary Allowance (RDA) for 
vitamin A is 900 mcg/day (3 000 units) for adult 
men and 700 mcg/day (2 300 units) for adult wom-
en (Sarubin, Thomson, 2007). Vitamin A is safe for 
most people in oral amounts less than 10 000 IU per 
day, as higher doses may lead to hypervitaminosis. 
Vitamin A is utilized for improving vision, treat-
ing macular degeneration, glaucoma, cataracts, skin 
conditions and infections.
Tamibarotene (Am80) is a synthetic retinoid act-
ing as a RAR agonist, a potential drug for Alzheimer’s 
disease (AD). This molecule controls multiple genes 
involved in some way in AD. In animal models, it 
showed promising properties of lowering the depo-
sition of insoluble amyloid-beta, reducing secretion 
of proinflammatory cytokines and chemokines, im-
proving brain vascularization and increasing the cor-
tical acetylcholine, reducing anxiety and improving 
sleep (Fukasawa et al., 2012). 
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Mega doses of vitamin A are now used in the 
therapy of cancer, HIV, and for dermatological pur-
poses (Vivat-Hannah, Zusi, 2005). Chronic vitamin 
A therapy should not exceed 3 000-4 000 IU daily 
because of liver toxicity (Nollevaux et al., 2006).
Hypervitaminosis A
Acute vitamin A toxicity occurs when adults ingest 
more than 100 times the RDA and children more 
than 20 times the RDA over a period of hours or a 
few days (Penniston, Tanumihardjo, 2006). Chronic 
toxicity occurs in subjects ingesting high doses of vi-
tamin A for months or years. 
Excessive or prolonged usage of vitamin A sup-
plementation can cause many central nervous sys-
tem problems such as irritability, anxiety, depression, 
cyclothymia, lethargy, insomnia, hypersomnolence, 
headache, sometimes even psychosis (Bremner et al., 
2012). In people living within the Arctic Circle, the 
pibloktoq syndrome (depression, explosive outbursts 
etc.) is thought to be the result of eating the internal 
organs of polar animals, known to have high vitamin 
A content (Bremner et al., 2012). 
CONCLUSION
A growing body of evidence testifies to the impor-
tant role of vitamin A in eye and brain functions. It 
is a necessary factor in brain and eye development 
and their adequate functioning in adults. Vitamin A 
regulates one-sixth of the brain genome, but also has 
extragenomic roles. Retinoids are involved in day and 
night vision, circadian and seasonal regulation, im-
munity, olfaction, hypothalamic and cognitive func-
tions, among others. An delicate balance of retinoids 
has to be kept for optimal function. There is only a 
narrow margin between deficiency and hypervita-
minosis, probably the narrowest among various sup-
plements. Higher levels can cause birth defects, de-
pression, anxiety, irritability, insomnia, headache and 
even psychosis. Hypovitaminosis A is among the ten 
leading causes of mortality and morbidity worldwide, 
especially in developing countries, but in developed 
countries it is mostly subclinically expressed. Vitamin 
A has a potential role in treating Alzheimer’s disease, 
autism spectrum disorders, Parkinson’s disease, cere-
bral ischemia, schizophrenia, as it is crucial in synap-
tic plasticity, neurogenesis in both in the developing 
brain and in adults. Clinicians should be aware of the 
importance of vitamin A and incorporate this knowl-
edge in their everyday practice.
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